Saturday, December 1, 2018

RHEA Generics and Fresenius Kabi team up to address chronic kidney disease

 From L-R: Mr. Neogin Evangelista, President & General Manager of Philusa Corporation; Ms. Ma. Rosario P. Dizon, GeneralManager of Fresenius Kabi, Philippines, Inc. ; Ms. Cora Lim, Vice President for Merchandising of Mercury Drug Corporation;Atty. Jeff Arzaga, Mercury Drug’s Legal Counsel.Manila, Philippines – RHEA Generics, a frontrunner of world-class and affordable medicines in the country, recentlyformalized its partnership with global healthcare company Fresenius Kabi, which will launch a new generic medicineaddressing chronic kidney disease in the Philippines. According to the National Kidney and Transplant Institute, over 10,800 Filipinos are affected by chronic kidneydisease, with tens of thousands of patients needing to undergo dialysis annually. Philusa Corporation President and General Manager Neogin Evangelista expressed, “Our latest collaboration withFresenius Kabi affirms our ceaseless pledge in delivering excellent quality medicines catering to a diverse set ofmedical concerns that is economically, and conveniently accessible to our fellow Filipinos. RHEA Generics will continue to work hand in hand with leading global pharmaceutical companies to ensure we are able to deliver ourpromise of offering generic medicines having the same quality, efficacy and safety of the innovator brands.” The new RHEA Generics drug, which will be exclusively available in all Mercury Drug stores nationwide starting November, in combination with a protein-restricted diet is an excellent drug that preserves the residual function of thekidneys of patients with Chronic Kidney Disease and delays its progression to dialysis.

No comments:

Post a Comment